Abstract: The invention relates an epoxysuccinamide derivative represented by a formula (I): ##STR1## wherein R.sup.1 represents a hydrogen atom, an alkyl or aminoalkyl group, R.sup.2 represents an aminoalkyl group which May be substituted, an aryl group which may be substituted, a heterocyclic group which may be substituted, an aralkyl group which may be substituted, or an alkyl group substituted by a heterocyclic ring which may be substituted, or R.sup.1 and R.sup.2 may form a nitrogen-containing heterocyclic ring, which may be substituted, together with the adjacent nitrogen atoms, and R.sup.3 and R.sup.4 are the same or different from each other and independently represent a hydrogen atom, or an alkyl or aralkyl group, or a salt thereof, a preparation process thereof, and a medicine comprising such a derivative or salt as an active ingredient.

Abstract: Substance FA-70D which has the following formula (1), or its salt, a method for its production, a pharmaceutical composition comprising the compound as an active ingredient, a method of treating osteoporosis which comprises administering the compound, use of the compound as a drug, and a microorganism capable of producing Substance FA-70D are disclosed. This compound has specific inhibitory activity against cathepsin series proteases and is of value as a therapeutic drug for various diseases, particularly osteoporosis, with which these enzymes are associated.

Abstract: The present invention provides a polypeptide having an amino acid sequence represented by Sequence No. 1 and a cathepsin L-specific inhibitor and therapeutic agent for osteoporosis comprising the polypeptide as its effective component. Since the polypeptide possesses potent inhibitory action specific to cathepsin L as well as strong bone resorption inhibitory action, the polypeptide is useful in the treatment of osteoporosis, particularly, senile osteoporosis.

Abstract: 5'-Pseudouridyl-N-oleoyl carbamate represented by the formula: ##STR1## This compound is physiologically active in that it markedly enhances the actions of glucocorticoids and hence is useful as an alternative to conventional steroid drugs.

Abstract: A 3'-polyphosphate of pyrimidine nucleoside or guanosine or a pharmaceutically acceptable salt thereof which has high antileukemial activity and is low in toxicity is disclosed.

Abstract: A glucocorticoid sparing factor (GSF) which amplifies liver enzyme induction which is caused in glucocorticoid and a process for the production of GSF are disclosed. GSF can be isolated from the culture broth of a microorganism of the Family Enterobacteriaceae.

Abstract: A glucocorticoid sparing factor (GSF) which amplifies to liver enzyme induction which is caused in glucocorticoid and a process for the production of GSF are disclosed. GSF can be isolated from the culture broth of a microorganism of the Family Enterobacteriaceae.